AnaCardio
CompanySweden
AnaCardio develops one asset, in phase 2 (AC01 in heart failure with reduced ejection fraction). Mostly small molecule; based in Sweden.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $89.9M
- 2
- Trials
- 2
- Signals
Pipeline
1Activates the ghrelin receptor to enhance cardiac contractility.
Phase 2, Small molecule, heart failure with reduced ejection fraction
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Funding rounds and grants2
- Signals5
- Similar companies6